Published in Genetics and Environmental Business Week, November 4th, 2004
Coronary artery disease affects 13 million people in the United States and is the leading cause of death for both men and women. The results of the study will be used to identify biomarkers that can aid disease diagnosis and potentially guide treatment options, as well as identify and prioritize new drug targets.
In this Novartis-funded study, ParAllele will utilize its proprietary Mismatch Repair Detection (MRD) technology to comprehensively discover novel Single Nucleotide...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.